Governing bodies

The Executive Steering Committee (ESC) is common to Ebola+ projects in which Janssen is participating and makes high-level decisions with regards to these Ebola+ projects. The ESC will be chaired by Janssen Vaccines & Prevention B.V.

The Clinical Steering Committee (CSC) is common to EBOVAC1 and EBOVAC2 projects and makes high-level decisions and approvals regarding implementation strategies and dispute resolution for issues arising from the Management Committee (MC). Issues that cannot be resolved by the CSC will be escalated to the ESC. The CSC will be chaired by Janssen. The EBOVAC2 Management Committee (MC) is in charge of the overall steering (contractual, clinical and scientific) of the project in line with the decisions made by the Clinical Steering Committee, the Executive Steering Committee and the advice provided by the External Advisory Groups. The EBOVAC2 MC will be chaired by Inserm.

Independent advisory boards

Scientific Advisory Boards

The Scientific Advisory Board (SAB) is a consultative body composed of independent inter-disciplinary scientific experts whose role is to provide scientific advice to all projects funded under the Ebola+ programme to ensure maximum impact in scientific, technological and health terms for all concerned parties. The SAB will, where and when relevant, review project deliverables, advise on scientific and technologic choices and for this purpose attend key project events. The SAB will be set up and managed by Inserm with the support of Inserm Transfert (EBOVAC2).

Ethics Board

The Ethics board will have a consultative role in the project and be asked, where and when relevant, to attend project meetings. The final list of sites, the final study protocol, approbation of Ethics Board, and clinical trial registration number will always be provided to IMI2JU. The Ethics Boards will be set up managed by LSHTM (EBOVAC1).